Patrick Flume to Male
This is a "connection" page, showing publications Patrick Flume has written about Male.
Connection Strength
0.951
-
Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest. 2021 12; 160(6):2042-2050.
Score: 0.041
-
Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2022 01; 21(1):96-103.
Score: 0.041
-
Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. J Cyst Fibros. 2021 11; 20(6):1003-1009.
Score: 0.040
-
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.
Score: 0.040
-
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros. 2021 03; 20(2):288-294.
Score: 0.039
-
Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. J Cyst Fibros. 2020 07; 19(4):569-574.
Score: 0.037
-
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):737-742.
Score: 0.034
-
Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. J Genet Couns. 2018 09; 27(5):1049-1054.
Score: 0.032
-
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
Score: 0.029
-
Aerosolized Antibiotics for Patients with Bronchiectasis. Am J Respir Crit Care Med. 2016 Apr 01; 193(7):808-10.
Score: 0.028
-
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9.
Score: 0.027
-
Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. J Cyst Fibros. 2015 Sep; 14(5):632-8.
Score: 0.026
-
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14.
Score: 0.026
-
Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis? Am J Respir Crit Care Med. 2014 Mar 01; 189(5):510-1.
Score: 0.025
-
Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. J Cyst Fibros. 2013 Jul; 12(4):403-6.
Score: 0.023
-
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724.
Score: 0.022
-
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med. 2011 Dec; 105 Suppl 2:S18-23.
Score: 0.021
-
Chronic cystic fibrosis respiratory infections: where do we go from here? Introduction. Respir Med. 2011 Dec; 105 Suppl 2:S1.
Score: 0.021
-
Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Sep; 8(5):321-5.
Score: 0.018
-
Making the diagnosis of cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):51-4.
Score: 0.016
-
Pneumothorax in cystic fibrosis. Chest. 2005 Aug; 128(2):720-8.
Score: 0.014
-
Massive hemoptysis in cystic fibrosis. Chest. 2005 Aug; 128(2):729-38.
Score: 0.014
-
An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis. 2005 Mar; 45(3):e41-4.
Score: 0.013
-
Testing two different doses of tiotropium Respimat? in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014; 9(9):e106195.
Score: 0.013
-
Transition programs in cystic fibrosis centers: perceptions of team members. Pediatr Pulmonol. 2004 Jan; 37(1):4-7.
Score: 0.012
-
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021 12 01; 204(11):1295-1305.
Score: 0.010
-
Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Sci Rep. 2021 07 09; 11(1):14232.
Score: 0.010
-
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest. 2021 09; 160(3):831-842.
Score: 0.010
-
Voice and Respiratory Characteristics of Men and Women Seeking Treatment for Presbyphonia. J Voice. 2022 Sep; 36(5):673-684.
Score: 0.010
-
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. J Cyst Fibros. 2021 01; 20(1):78-85.
Score: 0.010
-
Antimicrobial resistance: Concerns of healthcare providers and people with CF. J Cyst Fibros. 2021 05; 20(3):407-412.
Score: 0.009
-
Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414.
Score: 0.009
-
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.
Score: 0.009
-
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 12 15; 198(12):1559-1569.
Score: 0.009
-
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemp Clin Trials. 2018 01; 64:35-40.
Score: 0.008
-
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88.
Score: 0.008
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606.
Score: 0.008
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.
Score: 0.008
-
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017 09; 16(5):607-615.
Score: 0.008
-
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823.
Score: 0.008
-
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.
Score: 0.008
-
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):783-790.
Score: 0.007
-
Relief of the 'air hunger' of breathholding. A role for pulmonary stretch receptors. Respir Physiol. 1996 Mar; 103(3):221-32.
Score: 0.007
-
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40.
Score: 0.007
-
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502.
Score: 0.007
-
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8.
Score: 0.007
-
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb; 169:116-21.e2.
Score: 0.007
-
Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1.
Score: 0.007
-
Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.
Score: 0.007
-
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33.
Score: 0.007
-
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31.
Score: 0.007
-
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49.
Score: 0.006
-
Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7.
Score: 0.006
-
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014 May; 13 Suppl 1:S23-42.
Score: 0.006
-
Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant. 1994 Jan-Feb; 13(1 Pt 1):15-21; discussion 22-3.
Score: 0.006
-
The Fowler breathholding study revisited: continuous rating of respiratory sensation. Respir Physiol. 1994 Jan; 95(1):53-66.
Score: 0.006
-
Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013 Jul; 12(4):367-76.
Score: 0.006
-
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52.
Score: 0.005
-
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med. 2011 Dec; 105 Suppl 2:S9-17.
Score: 0.005
-
Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40.
Score: 0.005
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.
Score: 0.005
-
Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol. 2009 May-Jun; 30(3):150-2.
Score: 0.004
-
The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007 Jan-Feb; 21(1):122-7.
Score: 0.004
-
Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol. 2006 Jul; 41(7):683-7.
Score: 0.004
-
Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet. 2005 Nov 15; 14(22):3493-8.
Score: 0.003
-
Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004 Dec; 49(12):1504-8.
Score: 0.003
-
Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004 Jan; 48(1):281-4.
Score: 0.003
-
Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002 Mar; 73(3):922-6.
Score: 0.003
-
Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transpl. 2001 Dec; 7(12):1081-4.
Score: 0.003
-
Psychological functioning of adults with cystic fibrosis. Chest. 2001 Apr; 119(4):1079-84.
Score: 0.003
-
Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4.
Score: 0.002
-
A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999 May; 19(5):620-6.
Score: 0.002
-
The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7.
Score: 0.002